| 1 |
35277956 | Reassessing pharmacogenomic cell sensitivity with multilevel statistical models. | 2022 Mar 12 |
1 |
| 2 |
33386152 | Identification of a novel NPM1-ROS1 fusion in a lung adenocarcinoma and sensitive to crizotinib treatment. | 2021 Feb |
1 |
| 3 |
32573700 | IL10RA modulates crizotinib sensitivity in NPM1-ALK+ anaplastic large cell lymphoma. | 2020 Oct 1 |
1 |
| 4 |
30742941 | Crizotinib enhances anti-CD30-LDM induced antitumor efficacy in NPM-ALK positive anaplastic large cell lymphoma. | 2019 Apr 28 |
3 |
| 5 |
25727400 | Activity of second-generation ALK inhibitors against crizotinib-resistant mutants in an NPM-ALK model compared to EML4-ALK. | 2015 Jul |
1 |
| 6 |
25874976 | ALK kinase domain mutations in primary anaplastic large cell lymphoma: consequences on NPM-ALK activity and sensitivity to tyrosine kinase inhibitors. | 2015 |
1 |
| 7 |
25026277 | The ALK inhibitor ASP3026 eradicates NPM-ALK⁺ T-cell anaplastic large-cell lymphoma in vitro and in a systemic xenograft lymphoma model. | 2014 Jul 30 |
1 |
| 8 |
23239810 | Crizotinib-resistant NPM-ALK mutants confer differential sensitivity to unrelated Alk inhibitors. | 2013 Feb |
4 |